• Fill 3

    Cytokinetics is a late-stage biopharmaceutical company focused on discovering and developing potential medicines to improve healthspans in

    diseases of impaired muscle function

  • Fill 3

    Founded in 1997 by pioneers in muscle biology, we leverage unparalleled expertise to engineer compounds that

    target the sarcomere

  • Fill 3

    Cytokinetics has product research and development

    partnerships that power innovation and discovery

  • Fill 3

    We are inspired by the patients, caregivers and advocates in the communities we serve who

    fearlessly fight every day

  • Fill 3

    Empowering the future

    Strategic initiative to deepen and expand our pipeline

  • Fill 3

    Advancing muscle-biology
    driven potential therapies
    for diseases characterized by
    compromised muscle function,
    muscle weakness and fatigue

    Our areas of focus

    Cardiovascular Disease

    • Heart Failure
    • Hypertrophic Cardiomyopathy

    Neuromuscular Disease

    • Amyotrophic Lateral Sclerosis
    • Spinal Muscular Atrophy

Visit our corporate site

Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.

Visit our site

VV-MED-00769

Request Information
Group 14

Contact Information

Medical Information Request

Now Entering Cytokinetics Pipeline

Group 14

This information is intended for healthcare providers only. Compounds are investigational.
Inclusion in this display does not imply regulatory approval for these compounds in any indication.
Information about all Cytokinetics-sponsored trials can be found at cytokinetics.com/clinical-trials/

Continue to Pipeline

Now Leaving the Virtual Exhibit

Group 14

You are now exiting the Cytokinetics exhibit for the AHA Scientific Sessions 2020 Virtual Meeting. The link you’ve selected will take you to an external website.

Continue Offsite